Initially, the crucial effect of GK on glucose homeostasis was not accepted, and some studies could not imagine how agonists could activate GK similarly well in β cells in the pancreas and cells in the liver to maximize the effects of reducing glucose without any severe side effects, such as hyperlipidemia. Here, GK is linked to hyperlipidemia.